TickerWorth Open the interactive view →

Charles River Laboratories International, Inc. (CRL) — Available-Data Snapshot

Updated Nov 10, 2026 · available-data snapshot · descriptive, not a DCF, not advice

Price
$353.34
Market cap
$16,931,158,016
52-week high
$379.63
52-week low
$146.20
Currency
USD
Exchange
NYSE

We don't publish a discounted-cash-flow fair value for Charles River Laboratories International, Inc. (CRL) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.

On the numbers we do have, CRL trades at a recent price of $353.34, a market capitalisation of about $16,931,158,016, sitting 89% of the way up its 52-week range ($146.20–$379.63), on the NYSE.

The standard alternative to a DCF is relative valuation — comparing CRL's trading multiples against a sector benchmark. Here that gives P/E of 384.1× (richer than the peer median of 45.8×); Fwd P/E of 27.3× (richer than the peer median of 18.1×); P/B of 5.2× (cheaper than the peer median of 8.3×); P/S of 4.3× (cheaper than the peer median of 6.8×); EV/EBITDA of 21.6× (richer than the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. CRL shows a price-to-book (P/B) of 5.24 and book value of $67.40 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. CRL is in an up-trend (price above both its 50- and 200-day averages), trading -6.9% from its 52-week high. Over the past year the stock is +99.8%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

Relative valuation — CRL vs peers

MultipleCRLPeer median
P/E384.1×45.8×richer than
Fwd P/E27.3×18.1×richer than
P/B5.2×8.3×cheaper than
P/S4.3×6.8×cheaper than
EV/EBITDA21.6×18.5×richer than

Sector benchmark (bellwethers, not direct competitors).

Asset / book-value view

Price / book (P/B)
5.24
Book value / share
$67.40

Price-to-book compares the market price to the accounting net-asset value per share. Most useful for asset-heavy businesses, banks and insurers.

Price-based snapshot

50-day avg
$305.60
200-day avg
$224.56
From 52-wk high
-6.9%
1-year momentum
+99.8%

Price-based, not a valuation. Moving-average trend and 52-week position describe where the stock has traded — they say nothing about fair value.

Explore more

Most undervalued stocks (per our valuation) · All valued stocks · Interactive CRL view

A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is an educational tool, not a licensed investment adviser. Figures are estimates derived from public market data and can be wrong, stale or incomplete.